Phase 2 trial of talabostat in stage IV melanoma.

被引：0
|
作者：
Redman, BG
Ernstoff, MS
Gajewski, TF
Cunningham, C
Lawson, DH
Gregoire, L
Haltom, E
Uprichard, MJ
机构：
[1] Univ Michigan, Comp Canc Ctr, Ann Arbor, MI 48109 USA
[2] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA
[3] Univ Chicago, Chicago, IL 60637 USA
[4] Mary Crowley Med Res Ctr, Dallas, TX USA
[5] Emory Univ, Atlanta, GA 30322 USA
[6] Point Therapeut, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：727S / 727S
页数：1
相关论文
共 50 条
  • [31] A phase 2 trial of neoadjuvant biochemotherapy in stage 3 melanoma
    Gibbs, P
    Anderson, C
    Pearlman, N
    Becker, M
    O'Driscoll, M
    Stephens, J
    Baron, A
    Gonzalez, R
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 407 - 407
  • [32] A phase I trial with a hybrid cell vaccine in patients with metastatic melanoma.
    Trefzer, U
    Weingart, G
    Adrian, K
    Chen, Y
    Guo, YJ
    Audring, H
    Winter, H
    Walden, P
    Sterry, W
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1997, 109 (03) : 404 - 404
  • [33] Immunological results of a phase II randomized trial of multipeptide vaccines for melanoma.
    Slingluff, CL
    Petroni, G
    Bullock, KA
    Bissonnette, E
    Hibbitts, S
    Murphy, C
    Anderson, N
    Grosh, WW
    Neese, PY
    Fink, R
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 710S - 710S
  • [34] Phase II trial of extended-dosing temozolomide in patients with melanoma.
    Rietschel, P.
    Ejadi, S.
    Wolchok, J.
    Krown, S.
    Gerst, S.
    Jungbluth, A. A.
    Busam, K.
    Smith, K.
    Panageas, K.
    Chapman, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 463S - 463S
  • [35] Phase Ib/II trial of lenvatinib plus pembrolizumab in advanced melanoma.
    Taylor, Matthew H.
    Vogelzang, Nicholas J.
    Cohn, Allen Lee
    Stepan, Daniel E.
    Shumaker, Robert Charles
    Dutcus, Corina E.
    Guo, Matthew
    Schmidt, Emmett V.
    Rasco, Drew W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (08)
  • [36] A Phase 2 Trial of Complete Resection for Stage IV Melanoma Results of Southwest Oncology Group Clinical Trial S9430
    Sosman, Jeffrey A.
    Moon, James
    Tuthill, Ralph J.
    Warneke, James A.
    Vetto, John T.
    Redman, Bruce G.
    Liu, P. Y.
    Unger, Joseph M.
    Flaherty, Lawrence E.
    Sondak, Vernon K.
    CANCER, 2011, 117 (20) : 4740 - 4746
  • [37] Phase I trial of extended-dose anti-PD-1 antibody BMS-936558 with a multipeptide vaccine for previously treated stage IV melanoma.
    Kudchadkar, Ragini Reiney
    Gallenstein, Donna
    Martinez, Alberto J.
    Yu, Bin
    Weber, Jeffrey S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [38] Temozolomide (TMZ) plus thalidomide (THAL) as adjuvant therapy in patients with stage III and stage IV malignant melanoma.
    Hwu, WJ
    Coit, D
    Jaques, D
    Panageas, KS
    Lamb, LA
    Quinn, CJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 728S - 728S
  • [39] Randomized, double-blind, clinical trial of a polyvalent melanoma vaccine in patients with stage III melanoma.
    Bystryn, JC
    Oratz, R
    Shapiro, R
    Harris, M
    Roses, D
    Jacquotte, A
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1998, 110 (04) : 498 - 498
  • [40] Phase II study of HSPPC-96 in combination with GM-CSF and IFN-α in stage IV malignant melanoma.
    Parmiani, G
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 712S - 712S
12345